63 related articles for article (PubMed ID: 28366268)
1. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of Non-Covalent Imidazo[1,2-
Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors.
He P; Du L; Dai Q; Li G; Yu B; Chang L
Bioorg Chem; 2024 Jan; 142():106970. PubMed ID: 37984101
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and in vitro antitumor activity of 6-aryloxyl substituted quinazoline derivatives.
Fan M; Yao L
Turk J Chem; 2022; 46(3):849-858. PubMed ID: 37720611
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors.
Raghu MS; Swarup HA; Shamala T; Prathibha BS; Kumar KY; Alharethy F; Prashanth MK; Jeon BH
Heliyon; 2023 Sep; 9(9):e20300. PubMed ID: 37809937
[TBL] [Abstract][Full Text] [Related]
6. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells.
Jakobsen KR; Demuth C; Madsen AT; Hussmann D; Vad-Nielsen J; Nielsen AL; Sorensen BS
Oncogenesis; 2017 Apr; 6(4):e307. PubMed ID: 28368392
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
8. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K
Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
He M; Yang Z; Zhang L; Song C; Li Y; Zhang X
PLoS One; 2017; 12(4):e0175466. PubMed ID: 28399187
[TBL] [Abstract][Full Text] [Related]
11. Patient considerations in metastatic colorectal cancer - role of panitumumab.
Rogers JE
Onco Targets Ther; 2017; 10():2033-2044. PubMed ID: 28435294
[TBL] [Abstract][Full Text] [Related]
12. Exploratory cohort study and meta-analysis of
Sun S; Yu H; Wang H; Zhao X; Zhao X; Wu X; Qiao J; Chang J; Wang J
Onco Targets Ther; 2017; 10():1955-1967. PubMed ID: 28435285
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.
Tabchi S; Blais N
Front Oncol; 2017; 7():52. PubMed ID: 28424759
[TBL] [Abstract][Full Text] [Related]
14. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
[TBL] [Abstract][Full Text] [Related]
15. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
[TBL] [Abstract][Full Text] [Related]
16. Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Kwon BS; Park JH; Kim WS; Song JS; Choi CM; Rho JK; Lee JC
Tuberc Respir Dis (Seoul); 2017 Apr; 80(2):187-193. PubMed ID: 28416959
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
18. Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
Oncology; 2017; 93(1):62-66. PubMed ID: 28407622
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
[TBL] [Abstract][Full Text] [Related]
20. The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer.
Seo S; Woo CG; Lee DH; Choi J
Ann Oncol; 2017 Jul; 28(7):1667-1668. PubMed ID: 28407036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
